+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta-analysis



Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?: A meta-analysis



Diabetes Care 28(2): 454-460



OBJECTIVE:--To assess the value of granulocyte colony-stimulating factor (G-CSF) as adjunctive therapy for diabetic foot infections. RESEARCH DESIGN AND METHODS--We systematically searched the medical literature (including Medline, Embase, LookSmart, and the Cochrane Library) for prospective randomized studies that used G-CSF as an adjunct to standard treatment for diabetic foot infections. Using a conventional meta-analysis, we pooled the relative risks (RRs) for outcomes of interest, including resolution of infection, wound healing, duration of antibiotic therapy, and need for various surgical interventions, using a fixed-effects model. RESULTS:--Five randomized trials, with a total of 167 patients, met our inclusion criteria. The methodological quality of the studies was satisfactory. The investigators administered various G-CSF preparations parenterally for between 3 and 21 days. The meta-analysis revealed that adding G-CSF did not significantly affect the resolution of infection or the healing of the wounds but was associated with a significantly reduced likelihood of lower extremity surgical interventions (RR 0.38 [95% CI 0.20-0.69], number of patients who needed to be treated: 4.5), including amputation (0.41 [0.17-0.95], number of patients who needed to be treated: 8.6). There was no evidence of heterogeneity among the studies or of publication bias, suggesting that these conclusions are reasonably generalizable and robust. CONCLUSIONS:--Adjunctive G-CSF treatment does not appear to hasten the clinical resolution of diabetic foot infection or ulceration but is associated with a reduced rate of amputation and other surgical procedures. The small number of patients who needed to be treated to gain these benefits suggests that using G-CSF should be considered, especially in patients with limb-threatening infections.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 013082494

Download citation: RISBibTeXText

PMID: 15677817

DOI: 10.2337/diacare.28.2.454


Related references

Granulocyte-colony stimulating factors as adjunctive therapy for diabetic foot infections. Cochrane Database of Systematic Reviews (): Cd006810-Cd006810, 2014

Beneficial role of granulocyte colony stimulating factor in foot infection in diabetic patients. Journal of the Association of Physicians of India 51: 90-91, 2003

Adjunctive granulocyte colony-stimulating factor therapy for diabetic foot infections. Annals of PharmacoTherapy 38(12): 2150-2153, 2004

Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. Journal of Korean Medical Science 16(1): 39-44, 2001

Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer 10(3): 181-188, 2002

Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation. Journal of Clinical Oncology 24(33): 5207-5215, 2006

Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. Journal of Clinical Oncology 22(16): 3350-3356, 2004

Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer 37(2): 115-123, 2002

A Bayesian meta-analysis of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in children with cancer. American Journal of Epidemiology 163(9): 811-817, 2006

Granulocyte macrophage colony stimulating megakaryocyte colony stimulating eosinophil colony stimulating and erythroid colony stimulating factors produced by mouse spleen cells. Biochemical Journal 185(2): 301-314, 1980

Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. Bmc Cancer 11(): 404-404, 2012

Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Critical Care 15(1): R58-R58, 2011

Granulocyte-colony-stimulating factor in diabetic foot infection. Lancet 351(9099): 370-370, 1998

Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes, Obesity & Metabolism 3(5): 332-337, 2001

Evaluation of granulocyte-colony stimulating factor (Filgrastim) in infected diabetic foot ulcers. Diabetologia 46(1): 27-30, 2003